Behavioral and Cognitive Effects of Anti-epileptic Drugs

被引:0
|
作者
Cavanna, Andrea Eugenio [1 ,2 ]
Ali, Fizzah [1 ,2 ]
Rickards, Hugh Edward [1 ,2 ]
McCorry, Dougall [3 ]
机构
[1] Univ Birmingham, Dept Neuropsychiat, Birmingham B15 2FG, W Midlands, England
[2] Birmingham & Solihull Mental Hlth NHS Fdn Trust, Birmingham B15 2FG, W Midlands, England
[3] Univ Birmingham, Dept Neurol, Birmingham B15 2FG, W Midlands, England
关键词
DOUBLE-BLIND; LAMOTRIGINE; CARBAMAZEPINE; TOPIRAMATE; EFFICACY; EPILEPSY; LEVETIRACETAM; PSYCHOMOTOR; MONOTHERAPY; VIGABATRIN;
D O I
暂无
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Anti-epileptic drugs (AEDs) have a variety of mechanisms of action which are reflected through different anticonvulsant activities and behavioral effects. Two categories of AEDs are considered based on psychotropic profile. The first group is characterized by potentiation of gamma-aminobutyric acid (GABA) inhibitory neurotransmission, and comprises of agents such as vigabatrin, tiagabine, and gabapentin. These agents are noted to have sedating effects ranging from cognitive slowing to anti-manic effects. On the other hand, the second group is typified by attenuation of glutamate excitatory neurotransmission and has activating effects including anxiogenic and antidepressant actions. Lamotrigine and felbamate feature in this latter group. Mechanisms of action, chief clinical indications, as well as behavioral profile including comment on chief cognitive effects of the newer AEDs are reviewed in accordance with this dual categorization. In clinical practice, assessment of an individual patient alongside consideration of AED behavioral profile primes for appropriate prescription according to patient mood profile, also permitting exposure of AED-induced behavioral disturbance. [Discovery Medicine 9(45):138-144, February 2010]
引用
收藏
页码:138 / 144
页数:7
相关论文
共 50 条
  • [31] IMMUNOLOGICAL SIDE-EFFECTS OF ANTI-EPILEPTIC DRUGS (RECENT DATA) .3. EFFECTS OF ANTI-EPILEPTIC DRUGS ON THE IMMUNE-SYSTEM
    MAUGUIERE, F
    COURJON, J
    LYON MEDICAL, 1983, 249 (11): : 463 - 467
  • [32] PHARMACOKINETIC INTERACTIONS WITH ANTI-EPILEPTIC DRUGS
    GATTI, G
    PERUCCA, E
    LECCHINI, S
    FRIGO, GM
    CREMA, A
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY RESEARCH, 1982, 2 (04) : 95 - 100
  • [33] OSTEOMALACIA INDUCED BY ANTI-EPILEPTIC DRUGS
    DAVID, HP
    WOLOSZCZUK, W
    KOVARIK, J
    SEIDL, G
    ACTA MEDICA AUSTRIACA, 1982, 9 (03) : 7 - 7
  • [34] Biosensors technology for anti-epileptic drugs
    Mobed, Ahmad
    Shirafkan, Mahdiye
    Charsouei, Saeid
    Sadeghzadeh, Jafar
    Ahmadalipour, Ali
    CLINICA CHIMICA ACTA, 2022, 533 : 175 - 182
  • [35] HYPERCUPREMIA INDUCED BY ANTI-EPILEPTIC DRUGS
    GHOSE, K
    TAYLOR, A
    HUMAN TOXICOLOGY, 1983, 2 (03): : 519 - 529
  • [36] MECHANISMS OF ACTION OF ANTI-EPILEPTIC DRUGS
    WILDER, BJ
    BRUNI, J
    CLINICAL NEUROPHARMACOLOGY, 1982, 5 (01) : 23 - 43
  • [37] TERATOGENIC RISKS OF ANTI-EPILEPTIC DRUGS
    不详
    BRITISH MEDICAL JOURNAL, 1981, 283 (6290): : 515 - 516
  • [38] A PERSPECTIVE ON THE CHOICE OF ANTI-EPILEPTIC DRUGS
    SMITH, DB
    ELECTROENCEPHALOGRAPHY AND CLINICAL NEUROPHYSIOLOGY, 1982, 53 (06): : P85 - P86
  • [39] Anti-epileptic drugs in opiate addictions
    Vucetic-Arsic, S.
    Alcaz, S.
    EUROPEAN PSYCHIATRY, 2017, 41 : S883 - S883
  • [40] New anti-epileptic drugs in Paediatrics
    Malaga, Ignacio
    Sanchez-Carpintero, Rocio
    Roldan, Susana
    Ramos-Lizana, Julio
    Jose Garcia-Penas, Juan
    ANALES DE PEDIATRIA, 2019, 91 (06):